Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Recruiting · NCT05846789 · Registry updated 2026-09-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2026-09-03 | NCT05846789 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Breast Cancer Research Foundation | 40 |
| Genentech, Inc. | 221 |
| Kathy Miller | 1 |
| Susan G. Komen Breast Cancer Foundation | 16 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Duke University | Durham | United States | 45 |
| Emory University | Atlanta | United States | 262 |
| Indiana University Melvin and Bren Simon Comprehensive Cancer Center | Indianapolis | United States | 38 |
| IU Health Joe and Shelly Schwarz Cancer Center | Carmel | United States | 5 |
| Roswell Park Comprehensive Cancer Center | Buffalo | United States | 32 |
| Sidney and Lois Eskenazi Hospital | Indianapolis | United States | 58 |
| University of Kentucky-Lexington | Lexington | United States | 1 |